Lam Research (NASDAQ:LRCX) Stock Price Expected to Rise, Sanford C. Bernstein Analyst Says

Lam Research (NASDAQ:LRCX) had its price objective raised by Sanford C. Bernstein from $170.00 to $175.00 in a note issued to investors on Friday,MarketScreener reports. The firm presently has an “outperform” rating on the semiconductor company’s stock. Sanford C. Bernstein’s target price would suggest a potential upside of 22.68% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on LRCX. Raymond James Financial boosted their price objective on Lam Research from $90.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, July 31st. Barclays set a $142.00 target price on Lam Research and gave the stock an “equal weight” rating in a research report on Monday, October 20th. Erste Group Bank initiated coverage on shares of Lam Research in a report on Thursday, August 14th. They issued a “buy” rating on the stock. New Street Research lifted their price objective on shares of Lam Research from $105.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Finally, Citigroup boosted their price objective on shares of Lam Research from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, twenty-six have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $151.84.

Lam Research Trading Up 2.2%

Shares of NASDAQ LRCX opened at $142.65 on Friday. Lam Research has a 1-year low of $56.32 and a 1-year high of $167.15. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.21 and a quick ratio of 1.60. The business’s 50 day moving average is $144.17 and its two-hundred day moving average is $111.89. The stock has a market capitalization of $179.17 billion, a P/E ratio of 31.42, a PEG ratio of 1.68 and a beta of 1.87.

Lam Research (NASDAQ:LRCX) last released its earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.04. Lam Research had a return on equity of 60.60% and a net margin of 29.66%.The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.23 billion. During the same quarter in the previous year, the company posted $0.86 EPS. The company’s revenue for the quarter was up 27.7% compared to the same quarter last year. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. As a group, research analysts expect that Lam Research will post 3.71 EPS for the current year.

Insider Buying and Selling at Lam Research

In other news, SVP Vahid Vahedi sold 52,190 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $138.90, for a total value of $7,249,191.00. Following the completion of the sale, the senior vice president owned 251,047 shares of the company’s stock, valued at approximately $34,870,428.30. This represents a 17.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Douglas R. Bettinger sold 40,080 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $150.60, for a total transaction of $6,036,048.00. Following the completion of the transaction, the chief financial officer directly owned 987,237 shares of the company’s stock, valued at $148,677,892.20. This trade represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 102,608 shares of company stock worth $14,916,496. 0.31% of the stock is owned by company insiders.

Institutional Trading of Lam Research

Institutional investors have recently made changes to their positions in the business. Gilliland Jeter Wealth Management LLC raised its stake in Lam Research by 0.3% in the third quarter. Gilliland Jeter Wealth Management LLC now owns 26,501 shares of the semiconductor company’s stock valued at $3,548,000 after buying an additional 69 shares during the last quarter. Gold Investment Management Ltd. increased its holdings in shares of Lam Research by 0.5% during the third quarter. Gold Investment Management Ltd. now owns 14,736 shares of the semiconductor company’s stock valued at $1,973,000 after acquiring an additional 70 shares in the last quarter. Hemington Wealth Management raised its position in shares of Lam Research by 4.3% in the 3rd quarter. Hemington Wealth Management now owns 1,731 shares of the semiconductor company’s stock valued at $231,000 after purchasing an additional 72 shares during the last quarter. Magnus Financial Group LLC boosted its stake in Lam Research by 0.3% in the 3rd quarter. Magnus Financial Group LLC now owns 22,838 shares of the semiconductor company’s stock worth $3,058,000 after purchasing an additional 76 shares in the last quarter. Finally, Addison Advisors LLC grew its position in Lam Research by 2.8% during the 3rd quarter. Addison Advisors LLC now owns 2,857 shares of the semiconductor company’s stock worth $383,000 after purchasing an additional 77 shares during the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.